SWTX:NSD-SpringWorks Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 43.35

Change

-3.49 (-7.45)%

Market Cap

USD 3.63B

Volume

3.52M

Analyst Target

USD 54.40
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+3.15 (+0.72%)

USD 109.10B
REGN Regeneron Pharmaceuticals Inc

-10.23 (-1.05%)

USD 107.30B
MRNA Moderna Inc

+3.62 (+2.80%)

USD 44.96B
ARGX argenx NV ADR

-0.36 (-0.10%)

USD 22.43B
BNTX BioNTech SE

+0.78 (+0.85%)

USD 22.34B
ALNY Alnylam Pharmaceuticals Inc

+3.82 (+2.59%)

USD 18.64B
BGNE BeiGene Ltd

+6.15 (+3.73%)

USD 18.28B
GMAB Genmab AS

-0.57 (-1.89%)

USD 18.26B
BMRN Biomarin Pharmaceutical Inc

-3.43 (-4.27%)

USD 15.29B
TECH Bio-Techne Corp

-0.66 (-0.79%)

USD 13.26B

ETFs Containing SWTX

HFIN:CA Hamilton Enhanced Canadia.. 9.25 % 0.00 %

N/A

CAD 0.13B
XDIV:CA iShares Core MSCI Canadia.. 5.46 % 0.11 %

+0.15 (+0.29%)

CAD 1.23B
HMAX:CA Hamilton Canadian Financi.. 4.77 % 0.00 %

+0.04 (+0.29%)

CAD 0.76B
TLV:CA Invesco S&P/TSX Composite.. 2.38 % 0.34 %

+0.07 (+0.29%)

CAD 0.08B
XMD:CA iShares S&P/TSX Completio.. 1.83 % 0.61 %

+0.08 (+0.29%)

CAD 0.22B
RODM Hartford Multifactor Deve.. 0.93 % 0.31 %

-0.09 (0.29%)

USD 1.15B
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

-0.16 (0.29%)

USD 0.02B
CEW:CA iShares Equal Weight Banc.. 0.00 % 0.60 %

+0.02 (+0.29%)

CAD 0.20B
DXM:CA 0.00 % 0.67 %

N/A

N/A
FLI:CA CI U.S. & Canada Lifeco C.. 0.00 % 0.92 %

+0.06 (+0.29%)

CAD 0.09B
HEF:CA Horizons Enhanced Income .. 0.00 % 0.83 %

N/A

CAD 0.15B
HPR:CA Global X Active Preferred.. 0.00 % 0.63 %

+0.03 (+0.29%)

CAD 1.07B
PR:CA Lysander-Slater Preferred.. 0.00 % 1.03 %

-0.01 (0.29%)

CAD 0.08B
BNC:CA 0.00 % 0.68 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.77% 70% C- 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.77% 70% C- 82% B
Trailing 12 Months  
Capital Gain 83.38% 87% B+ 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 83.38% 87% B+ 92% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 23.32% 75% C 82% B
Dividend Return 23.32% 75% C 81% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 77.39% 35% F 21% F
Risk Adjusted Return 30.14% 83% B 65% D
Market Capitalization 3.63B 94% A 86% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector